Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Graphical Abstract
Current Drug Metabolism
Title:Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Volume: 22 Issue: 7
Author(s): Md. Marufur Rahman Moni, Mst. Marium Begum, Md. Sahab Uddin*Ghulam Md Ashraf*
Affiliation:
- Department of Pharmacy, Southeast University, Dhaka,Bangladesh
- Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Export Options
About this article
Cite this article as:
Moni Marufur Rahman Md. , Begum Marium Mst. , Uddin Sahab Md. *, Ashraf Md Ghulam*, Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease, Current Drug Metabolism 2021; 22 (7) . https://dx.doi.org/10.2174/1389200222666210202110129
DOI https://dx.doi.org/10.2174/1389200222666210202110129 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Parkinson’s Disease: A Current Perspectives on Parkinson’s Disease and Key Bioactive Natural Compounds as Future Potential Drug Candidates
Current Drug Targets Pharmacologic Treatments in “Prodromal Psychosis:” Making Clinical Decisions in the Absence of a Consensus
Adolescent Psychiatry On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger
Drug Metabolism Letters Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Recent Advances on Nitric Oxide in the Upper Airways
Current Medicinal Chemistry Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders
Current Psychopharmacology Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism